Infliximab in ulcerative colitis
Avi Levin, Oren ShiboletGastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, IsraelAbstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). I...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d7d25d975b084e1b95110d58fe7dcd89 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Avi Levin, Oren ShiboletGastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, IsraelAbstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC.Keywords: infliximab, ulcerative colitis, anti-TNF-α antibody, crohn’s disease |
|---|